The diagnosis of esophageal cancer by 2-deoxy-2-F-18 fluoro-D-glucose positron emission tomography (F-18 FDG PET)

Mohab Alexander; James Robert Brašić

doi:10.1097/01.rlu.0000233350.01580.c2

The diagnosis of esophageal cancer by 2-deoxy-2-F-18 fluoro-D-glucose positron emission tomography (F-18 FDG PET)

Mohab Alexander, James Robert Brašić

School of Medicine

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

FDG PET plays an essential role in the diagnosis and treatment of patients with esophageal carcinoma. A 67-year-old man, who presented with dysphagia, fatigue, weakness, anorexia, anergia, and weight loss, underwent Tc-99m bone scan, CT, and FDG PET imaging. The bone scan and CT were consistent with a malignancy. Whole-body FDG PET demonstrated multiple metastases in various locations and helped the treating physicians to institute appropriate therapy. The identification of metastases by FDG PET is a critical component of the initial evaluation of a patient with esophageal carcinoma for the diagnosis and treatment of the primary malignancy and metastases.

Original language	English (US)
Pages (from-to)	566-567
Number of pages	2
Journal	Clinical nuclear medicine
Volume	31
Issue number	9
DOIs	https://doi.org/10.1097/01.rlu.0000233350.01580.c2
State	Published - Sep 1 2006

Keywords

Carcinoma
Dysphagia
Esophagus
Malignancy
Metastases
Radiation therapy

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1097/01.rlu.0000233350.01580.c2

Cite this

@article{d3102eabab0641389b7f803930f19fde,

title = "The diagnosis of esophageal cancer by 2-deoxy-2-F-18 fluoro-D-glucose positron emission tomography (F-18 FDG PET)",

abstract = "FDG PET plays an essential role in the diagnosis and treatment of patients with esophageal carcinoma. A 67-year-old man, who presented with dysphagia, fatigue, weakness, anorexia, anergia, and weight loss, underwent Tc-99m bone scan, CT, and FDG PET imaging. The bone scan and CT were consistent with a malignancy. Whole-body FDG PET demonstrated multiple metastases in various locations and helped the treating physicians to institute appropriate therapy. The identification of metastases by FDG PET is a critical component of the initial evaluation of a patient with esophageal carcinoma for the diagnosis and treatment of the primary malignancy and metastases.",

keywords = "Carcinoma, Dysphagia, Esophagus, Malignancy, Metastases, Radiation therapy",

author = "Mohab Alexander and Bra{\v s}i{\'c}, {James Robert}",

year = "2006",

month = sep,

day = "1",

doi = "10.1097/01.rlu.0000233350.01580.c2",

language = "English (US)",

volume = "31",

pages = "566--567",

journal = "Clinical nuclear medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins",

number = "9",

}

TY - JOUR

T1 - The diagnosis of esophageal cancer by 2-deoxy-2-F-18 fluoro-D-glucose positron emission tomography (F-18 FDG PET)

AU - Alexander, Mohab

AU - Brašić, James Robert

PY - 2006/9/1

Y1 - 2006/9/1

N2 - FDG PET plays an essential role in the diagnosis and treatment of patients with esophageal carcinoma. A 67-year-old man, who presented with dysphagia, fatigue, weakness, anorexia, anergia, and weight loss, underwent Tc-99m bone scan, CT, and FDG PET imaging. The bone scan and CT were consistent with a malignancy. Whole-body FDG PET demonstrated multiple metastases in various locations and helped the treating physicians to institute appropriate therapy. The identification of metastases by FDG PET is a critical component of the initial evaluation of a patient with esophageal carcinoma for the diagnosis and treatment of the primary malignancy and metastases.

AB - FDG PET plays an essential role in the diagnosis and treatment of patients with esophageal carcinoma. A 67-year-old man, who presented with dysphagia, fatigue, weakness, anorexia, anergia, and weight loss, underwent Tc-99m bone scan, CT, and FDG PET imaging. The bone scan and CT were consistent with a malignancy. Whole-body FDG PET demonstrated multiple metastases in various locations and helped the treating physicians to institute appropriate therapy. The identification of metastases by FDG PET is a critical component of the initial evaluation of a patient with esophageal carcinoma for the diagnosis and treatment of the primary malignancy and metastases.

KW - Carcinoma

KW - Dysphagia

KW - Esophagus

KW - Malignancy

KW - Metastases

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=33747618246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747618246&partnerID=8YFLogxK

U2 - 10.1097/01.rlu.0000233350.01580.c2

DO - 10.1097/01.rlu.0000233350.01580.c2

M3 - Article

C2 - 16921288

AN - SCOPUS:33747618246

SN - 0363-9762

VL - 31

SP - 566

EP - 567

JO - Clinical nuclear medicine

JF - Clinical nuclear medicine

IS - 9

ER -

The diagnosis of esophageal cancer by 2-deoxy-2-F-18 fluoro-D-glucose positron emission tomography (F-18 FDG PET)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this